XBiotech Inc. (XBIT)
NASDAQ: XBIT · IEX Real-Time Price · USD
5.99
+0.02 (0.34%)
Jul 22, 2024, 10:22 AM EDT - Market open
XBiotech Employees
XBiotech had 82 employees as of December 31, 2023. The number of employees decreased by 3 or -3.53% compared to the previous year.
Employees
82
Change (1Y)
-3
Growth (1Y)
-3.53%
Revenue / Employee
n/a
Profits / Employee
-$374,915
Market Cap
182.14M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accuray | 1,024 |
Metagenomi | 236 |
Seres Therapeutics | 233 |
908 Devices | 230 |
Inhibrx | 172 |
OptimizeRx | 136 |
Biomea Fusion | 103 |
Candel Therapeutics | 42 |
XBIT News
- 4 weeks ago - What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? - Benzinga
- 4 weeks ago - XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer - GlobeNewsWire
- 7 months ago - XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus - GlobeNewsWire
- 8 months ago - Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - GlobeNewsWire
- 10 months ago - XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke - GlobeNewsWire
- 11 months ago - XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer - GlobeNewsWire
- 1 year ago - XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial - GlobeNewsWire
- 1 year ago - FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients - GlobeNewsWire